ABSTRACT ABVD is associated with severe toxicity in older patients, particularly due to bleomycininduced lung toxicity (BLT). Therefore, the use of bleomycin has been questioned in older HL patients, especially in early-stage HL.
KEY POINTS
• Two cycles ABVD or AVD were equally tolerable in older early-stage favorable Hodgkin lymphoma patients
• Excessive toxicity including severe bleomycin-induced lung toxicity occurred in older HL patients receiving 4 cycles ABVD
ABSTRACT
ABVD is associated with severe toxicity in older patients, particularly due to bleomycininduced lung toxicity (BLT). Therefore, the use of bleomycin has been questioned in older HL patients, especially in early-stage HL.
We therefore analyzed feasibility, toxicity and efficacy of ABVD or AVD in 287 older earlystage favorable HL patients. We included patients ≥ 60 years of age in the GHSG HD10 and HD13 trials randomized to either 2 cycles ABVD (n=137) or AVD (n=82), each followed by involved-field radiotherapy (IF-RT), and patients randomized to 4xABVD+IF-RT (n=68).
Patients had a median age of 65 years (range 60-75) and comparable patient and disease characteristics. Rates of grade III-IV adverse events were similar in patients receiving 2xAVD and 2xABVD (40% and 39%, respectively), but considerably higher in patients receiving 4xABVD (65%). Similarly, BLT was rare in patients receiving 2xABVD/AVD, but occurred in 7/69 (10%) of the patients randomized to 4xABVD with three lethal events.
In conclusion, no effects of bleomycin on toxicity rates were detectable in older patients receiving 2 cycles of chemotherapy. However, we found a high risk of severe toxicity of bleomycin in older HL patients receiving more than two cycles of ABVD.
The trials are registered to www.clinicaltrials.gov and www.isrctn.com with the numbers NCT00265018 (HD10) and ISRCTN63474366 (HD13). [2] [3] [4] [5] [6] . However, ABVD is associated with severe toxicity in older patients, particularly due to bleomycin-induced lung toxicity (BLT) 2, [6] [7] [8] [9] . Therefore, the use of bleomycin has been questioned in older HL patients, especially in early-stage HL 10, 11 .
We recently reported results of a large randomized prospective trial comparing ABVD variants omitting bleomycin, dacarbazine or both in early-stage favorable HL 12 . Omission of bleomycin resulted in an increased risk of relapse compared with standard ABVD-treatment in this trial including patients aged 18 to 75 years. However, whether the benefits of bleomycin in terms of efficacy outweigh the higher risk of severe toxicity in older patients remains unknown.
We therefore investigated the impact of bleomycin in the ABVD regimen in older (≥60 years) early-stage favorable HL patients by comparing feasibility, toxicity and efficacy of 2xABVD or 2xAVD followed by 20 or 30 Gy involved-field radiotherapy (IF-RT). In addition, to measure cumulative toxic effects, we analyzed older patients who received 4xABVD followed by IF-RT in the HD10 trial 13 .
METHODS
The HD10 and HD13 trials conducted by the German Hodgkin Study Group (GHSG) included early-stage favorable HL patients defined as clinical stages I and II without any of the GHSG risk factors 12, 13 .
Both trials were approved by the ethics committees of all participating centers and conducted in accordance with the Declaration of Helsinki. The trials were registered with the numbers NCT00265018 (HD10) and ISRCTN63474366 (HD13), both trials were funded by Deutsche
Krebshilfe and the Swiss Federal Government.
Detailed information on both trials has been published previously 12, 13 . ABVD consisted of doxorubicin 25 mg/m 2 , bleomycin 10 mg/m 2 , vinblastine 6 mg/m 2 and dacarbazine 375 mg/m 2 each administered on day 1 and day 15 of a 29 day schedule.
Both trials included pulmonary function testing (PFT) before enrolment without cutoff-DLCO; patients with pulmonary disease prohibiting therapy according to protocol were deemed ineligible. PFT was repeated at follow up or in case of suspected BLT 12, 13 . BLT was defined as documented grade 3-4 adverse event of the category "respiratory tract disorders" in For personal use only. on October 4, 2017. by guest www.bloodjournal.org From relation to bleomycin administration with severity ranging from dyspnea to interstitial pneumonitis and lung fibrosis.
We compared outcomes and toxicity rates using Fisher's exact test and analyzed survival endpoints according to the Kaplan-Meier method. Analyses were done with SAS version 9.4 (SAS Institute, Cary, NC).
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RESULTS AND DISCUSSION
287 patients (median age 65 years; range 60-75) were included with an equal distribution of patient-and disease-characteristics (table 1) . 137, 82 and 68 patients were randomized to receive 2xABVD (HD10 and HD13), 2xAVD (HD13), and 4xABVD (HD10), respectively.
Early termination of treatment was reported in 2/82 (2%) and 5/137 (4%) of the patients randomized to receive 2xAVD and 2xABVD, respectively. In contrast, 12/68 (18%) of the patients randomized to receive 4xABVD terminated therapy early, mainly due to toxicity. Accordingly, patients receiving 2 cycles of chemotherapy were more likely to receive the correct number of chemotherapy cycles and had shorter mean delay of chemotherapy than patients randomized to 4xABVD (table 1) .
Overall, frequency of grade III-IV adverse events was similar for patients receiving 2xAVD and 2xABVD (40% and 39%, respectively, table 1). Importantly, overall grade III-IV toxicity and grade III-IV leukopenia and infection rates were much higher in patients receiving 4xABVD.
In patients receiving two cycles of chemotherapy, respiratory adverse events were rare: BLT was reported in two and no cases with 2xABVD and AVD (1.5% and 0%), respectively. In striking contrast, BLT occurred in 7 patients (10%) receiving 4xABVD and was lethal in three of the affected patients (table 1) . This is in line with previous findings reporting BLT rates in older HL patients of about 5%-36% and an associated lethality of up to 25% 6, 8 .
Interestingly, a recent retrospective analysis including older patients with mostly advancedstage HL found, that pulmonary toxicity was the most frequent toxicity with a total incidence of BLT of 27% and that five of the seven patients who died of pulmonary toxicity had received more than two cycles ABVD Regarding the efficacy in our study, remission rates and rates of progression and relapse were excellent in all treatment groups. Rates of complete remission (CR) ranged between 96-99% in the groups receiving two cycles of chemotherapy (table 1) in line with previously reported findings 2, 6, 8, 11 . In contrast, the CR rate was only 88% after 4xABVD, partly resulting from a higher number of deaths during therapy in this treatment group.
Patient numbers in our study were too small for testing on (non-)inferiority of the AVD regimen (table 1) . However, since efficacy of 2xABVD was not substantially impaired in older patients, we found no evidence for refraining from the efficacy conclusions drawn from the HD13 trial, which included both younger and older patients ( figure 1, table 1 ) 12 .
Our findings indicate that the influence of bleomycin on efficacy observed in the HD13 trial should also be considered for the subgroup of older patients and that two cycles of ABVD can be safely applied in this presumably more vulnerable patient population. However, our findings do not support the use of bleomycin beyond two cycles in ABVD for older HL patients, as would be warranted in certain situations 15 . In older early-stage favorable patients, combined modality treatment should thus be favored over three to four cycles of chemotherapy alone. In early-stage unfavorable and advanced-stage patients requiring more than 2xABVD, bleomycin might be omitted in subsequent cycles. In addition, caution is warranted in the use of bleomycin for older patients with risk-factors for BLT described previously, such as renal insufficiency, pulmonary radiation, underlying lung disease, tobacco history and concomitant use of G-CSF 7, 16 . However, due to the small number of older patients in our study experiencing BLT, we were not able to confirm these risk factors in our analysis.
As another limitation of our study, comprehensive geriatric assessment, which might help to predict toxicity, was not included in the HD10 and HD13 as it is mandatory part of ongoing GHSG trials in older HL.
In conclusion, in 219 older early-stage favorable HL patients treated with either 2xABVD or 2xAVD both followed by IF-RT, no significant effects of bleomycin on the incidence and severity of adverse events were detectable. In contrast, the additional 68 older patients receiving 4xABVD had more grade III-IV toxicity and a strikingly higher rate of BLT, suggesting a high risk of severe toxicity and limited benefit in older HL patients receiving more than two cycles of bleomycin. provided patients, collected and analyzed data and critically reviewed the manuscript before submission.
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